Immunomodulation for glioblastoma.


PURPOSE OF REVIEW Immunotherapy has emerged as a cornerstone of modern oncology with regulatory approvals for a variety of immunotherapeutics being achieved for a spectrum of cancer indications. Nonetheless the role of these approaches for patients with glioblastoma (GBM), the most common and deadliest primary malignant brain neoplasm, remains unknown. In… (More)
DOI: 10.1097/WCO.0000000000000451


2 Figures and Tables

Cite this paper

@article{Reardon2017ImmunomodulationFG, title={Immunomodulation for glioblastoma.}, author={David A Reardon and Patrick Yung Chih Wen and Kai W Wucherpfennig and John H. Sampson}, journal={Current opinion in neurology}, year={2017}, volume={30 3}, pages={361-369} }